Latest news with #NetworkNewsWire
Business Upturn
07-08-2025
- Business
- Business Upturn
Nightfood Holdings Inc. (NGTF) Leading Hospitality Innovation with Business Model Fusing Hotel Ownership, AI and Robotics
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Nightfood Holdings inc. (NGTF) today announces its placement in an editorial published by NetworkNewsWire ('NNW'), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ) , a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, 'AI, Robotics Are Reshaping the Future of Hospitality,' please visit: The hospitality industry is rapidly evolving as artificial intelligence (AI) and robotics bring sweeping change. Hotels that implement automation are seeing operational costs drop by 30%–40%, along with enhanced guest satisfaction and stronger revenue strategies. The AI-driven hospitality market is projected to surge to $1.46 billion by 2029 with an impressive 57.8% compound annual growth rate (CAGR), while the broader hospitality robotics sector is anticipated to expand from $24.38 billion in 2024 to $107.24 billion by 2034. At the forefront of this transformation is Nightfood Holdings Inc., an innovator in hospitality that fuses hotel ownership with a Robotics-as-a-Service (RaaS) business model powered by AI. The company recently disclosed plans to purchase a 155-room Holiday Inn in Victorville, California, marking its debut model property featuring guest-facing robots such as food runners and laundry assistants, developed by NGTF subsidiary Skytech Automated Solutions. Nightfood also partnered with Bear Robotics to roll out these automation solutions across its entire hotel portfolio, which is expected to grow to $80 million in assets. About Nightfood Holdings inc. Nightfood Holdings, Inc. is revolutionizing the hospitality industry by combining AI-powered robotics with strategic hotel acquisitions. The Company's innovative approach uses advanced automation technology to significantly improve hotel efficiency, reduce operating costs, and address labor challenges. As automation rapidly becomes the standard rather than a trend in hospitality, Nightfood is committed to setting that standard — delivering intelligent solutions that enhance guest experiences and streamline operations. With its dual focus on owning hotel properties and offering Robotics-as-a-Service (RaaS), NGTF is strategically positioned to capitalize on the rapidly growing global service robotics market, which is expected to surpass $170 billion by 2030. This integrated business model provides scalable revenue streams and positions NGTF as a leader in technology-driven hospitality solutions. NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company's newsroom at For more information, visit the company's website at About NetworkNewsWire NetworkNewsWire ('NNW') is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: NetworkNewsWireNew York, Office [email protected]
Cision Canada
06-08-2025
- Business
- Cision Canada
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /CNW/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments. The Trump administration's "Make America Healthy Again" initiatives have highlighted this problem and focused on improving access to treatments and speeding up medical innovation. Soligenix Inc. (NASDAQ: SNGX) (Profile) is working to advance this mission with its HyBryte(TM) platform, a new therapy for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer that largely impacts older adults. The company has successfully established U.S.-based manufacturing for HyBryte's active ingredient, demonstrating the kind of domestic innovation that can significantly help this underserved patient group. Soligenix is one of several notable companies dedicated to making an impact in the pharmaceutical field, alongside Amgen Inc. (NASDAQ: AMGN), Amicus Therapeutics Inc. (NASDAQ: FOLD), Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Citius Oncology Inc. (NASDAQ: CTOR). Soligenix's HyBryte program is a promising treatment option for cutaneous T-cell lymphoma (CTCL), a rare cancer that largely impacts older adults. In 2024, the global market for CTCL therapies in the seven major markets (the United States, EU4, the United Kingdom, and Japan) was estimated to be around $995 million. Soligenix is conducting a second confirmatory phase 3 clinical trial for HyBryte, which is a crucial step in moving the therapy toward global commercialization. One of HyBryte's most important strengths in the treatment of cutaneous T-cell lymphoma (CTCL) is its consistently favorable safety record. Click here to view the custom infographic of the Soligenix Inc. editorial. Chronic Conditions Demand Targeted Innovation Chronic rare diseases are becoming a major challenge for the aging population in the United States. As life expectancy rises, healthcare needs become more complex, especially for conditions that are long-lasting and hard to diagnose. With tens of millions of Americans living with a rare disease, many of whom are seniors whose symptoms might be dismissed as normal signs of aging, there is a clear and growing need for better care. Since rare diseases can present subtly or mimic common age-related issues, older adults often face diagnostic delays of years, which can hinder access to effective care and lead to worse outcomes. The problem is made worse by the limited number of FDA-approved treatments. With thousands of uncommon diseases identified, most still do not have approved therapies, which highlights the importance of ongoing investment in research and development. Seniors are particularly susceptible to underdiagnosis and undertreatment, especially when the healthcare system isn't prepared to recognize the subtle ways these conditions manifest in older adults. President Trump's "Make America Healthy Again" initiative has drawn attention to the increasing burden of chronic and rare diseases. These efforts, which include policies aimed at accelerating research, improving diagnostic tools, and expanding access to care, are designed to meet the needs of older Americans facing these complicated health challenges. Savvy companies such as Soligenix Inc. are stepping up to address this need. The company's HyBryte program is a promising treatment option for cutaneous T-cell lymphoma (CTCL), a rare cancer that largely impacts older adults. Soligenix has recently completed the successful U.S. manufacturing transfer of HyBryte's active ingredient, which helps the company's mission to provide effective, innovative treatments to patients who need them most. Growing CTCL Market Highlights Urgency Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin's lymphoma (NHL) that mainly affects the skin. Unlike other lymphomas, CTCL involves malignant T-cells that move to the skin's surface, where they form patches, lesions, or tumors. This chronic cancer is most often seen in older adults, making it particularly relevant to the aging population. Despite its rarity, CTCL is a serious medical issue, affecting over 40,000 NHL patients worldwide. Currently, there is no cure for CTCL, and treatments are typically focused on managing symptoms and slowing the disease's progression. Mycosis fungoides (MF) is the most common subtype of CTCL, accounting for about 90% of all cases. In its early stages (I–IIA), MF has a relatively high five-year survival rate of 88%, but it remains a lifelong illness. As a chronic condition with no approved first-line therapy for early-stage patients, CTCL represents a clear unmet medical need. In 2024, the global market for CTCL therapies in the seven major markets (the United States, EU4, the United Kingdom, and Japan) was estimated to be around $995 million, with the U.S. making up approximately 70% of that total. Additionally, DelveInsight notes that "the expected launch of therapies such as HyBryte . . . will also boost the CTCL market growth." In the absence of novel therapies, treatment choices remain scarce, particularly for individuals diagnosed in the early phases of the disease. Numerous patients cycle through multiple therapies with minimal results, underscoring the urgent demand for more precise and effective treatment options. HyBryte (synthetic hypericin) from Soligenix represents a compelling candidate to serve as a first-line treatment for early-stage CTCL. Addressing a crucial unmet need, HyBryte has the potential to greatly enhance patient well-being and emerge as a top therapeutic choice within this largely unaddressed segment of the market. Pivotal Trial Advances Global Approval Soligenix is currently conducting a second confirmatory phase 3 clinical trial for HyBryte, called FLASH2, which is a crucial step in moving the therapy toward global commercialization for the treatment of early-stage CTCL. The FLASH2 study is designed to confirm the positive results of the first FLASH study and has been accepted by the European Medicines Agency (EMA), with ongoing discussions with the U.S. Food and Drug Administration (FDA). The EMA's validation of the trial design shows its strength and its alignment with international standards for therapeutic approval. The FLASH2 study is similar to its predecessor but features a longer, 18-week double-blind, placebo-controlled treatment period, which is three times longer than the original six-week period in the first FLASH trial. This extended timeline is expected to provide more comprehensive data on HyBryte's safety and effectiveness. Importantly, key elements such as the patient inclusion and exclusion criteria and the primary endpoint are consistent between the two studies, which supports the integrity and comparability of the trial outcomes. An estimated 80 patients will be enrolled at clinical sites in both the United States and Europe. This multinational approach is intended to support broad regulatory submissions and clear the way for HyBryte's commercial launch on a global scale. With enrollment on schedule, Soligenix expects to report top-line results in 2026. These data could significantly strengthen the case for HyBryte to become the first approved front-line treatment for early-stage CTCL. As Soligenix continues to advance this promising therapy, FLASH2 represents a potentially transformative milestone in the company's efforts to address a long-standing unmet medical need within the rare disease and oncology communities. Trial Results Reinforce HyBryte's Promise Soligenix's HyBryte has reached a key milestone with the successful completion of its first phase 3 clinical trial, known as the FLASH study, delivering statistically significant positive results and marking a major step forward in the treatment of early-stage cutaneous T-cell lymphoma (CTCL). Recognized for addressing a critical unmet medical need, HyBryte has been granted orphan drug designation in both the United States and European Union, along with Fast Track status by the FDA. In contrast to many existing CTCL therapies that often require a year or more to demonstrate effectiveness, HyBryte produced statistically meaningful clinical responses in only six weeks. Continued treatment further increased efficacy, with response rates climbing to 40% at 12 weeks and reaching 49% at 18 weeks. Importantly, the therapy proved effective across both surface-level patch lesions and deeper plaque lesions, a distinction that sets it apart from many current early-stage CTCL treatments, which tend to show efficacy primarily in patch-type disease. This broader impact across lesion types underscores HyBryte's differentiated potential in managing this heterogeneous and challenging condition. The structure and outcomes of the study reinforce the promise of HyBryte as a practical, noninvasive therapeutic option that could redefine care for CTCL patients. HyBryte also stands out for its strong safety and tolerability profile. Results from the FLASH trial showed very few adverse events, which is a notable advantage compared to other CTCL treatments that can cause significant short- and long-term side effects. This makes HyBryte especially well-suited for older patients who may be dealing with other health issues and are particularly sensitive to treatment-related complications. Another innovative feature of HyBryte is its use of visible fluorescent light rather than traditional ultraviolet (UV) light for activation. This approach eliminates the carcinogenic risks that are commonly associated with conventional phototherapy, providing a safer treatment experience while preserving therapeutic efficacy. The activation of synthetic hypericin by safe, visible light enhances both safety and convenience for patients. Taken together, the results from the FLASH and ongoing FLASH2 studies establish HyBryte as a compelling front-runner to become the first approved primary treatment for early-stage CTCL, offering a faster-acting, safer, and more comprehensive alternative to existing standards of care. Safety and Market Potential Align One of HyBryte's most important strengths in the treatment of cutaneous T-cell lymphoma (CTCL) is its consistently favorable safety record, as demonstrated across several clinical trials. In contrast to many currently approved therapies for early-stage CTCL, which are frequently linked to serious or even life-threatening side effects, HyBryte has shown excellent tolerability with no safety issues reported so far. Its unique mechanism of action does not involve DNA damage—an important advantage in a therapeutic space where numerous treatments pose risks such as melanoma, other forms of cancer, significant skin injury, and accelerated skin aging. This strong safety profile takes on even greater importance given that existing CTCL treatments are only sanctioned for use after other options have failed, and none are approved for initial, front-line use. In such a landscape, safety considerations weigh heavily in treatment decisions, especially for older patients who may also be managing other medical conditions. HyBryte's properties, including low systemic absorption, its nonmutagenic active compound, and the use of visible, non-carcinogenic light for activation, set it apart as a particularly safe and practical option. With no first-line therapies currently available, HyBryte is well positioned to fill that critical gap by combining safety with clinical effectiveness. Beyond its strong therapeutic potential, HyBryte also presents a substantial commercial opportunity in a market that remains largely underserved. Analysts estimate the global CTCL treatment market to exceed $990 million, highlighting the significant demand for innovative and effective therapies. As clinical development progresses, HyBryte has the potential not only to transform outcomes for patients but also to emerge as a new standard of care in CTCL management, meeting urgent clinical needs while offering a scalable solution for healthcare providers and investors alike. Advancements in Oncology Research The world of pharmaceutical research is continually evolving, and recent announcements from several key players in the biopharma space highlight significant progress. From promising clinical trial results to strategic partnerships aimed at broadening market reach, these developments offer new hope for patients and clinicians alike. Amgen Inc. is reporting results on its phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6). According to the company, the trial met its primary endpoint of overall survival (OS) at a prespecified interim analysis. The company noted that "bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive." Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and more than 650,000 deaths globally each year, highlighting a critical unmet medical need. Amicus Therapeutics Inc. recently announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study. The study evaluated cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD). The report was published in " Muscle and Nerve." In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured. Tonix Pharmaceuticals Holding Corp. is reporting the publication of a paper in the peer-reviewed journal " Cancer Cell." The paper, titled "A CXCR4 Partial Agonist, Improves Immunotherapy by Targeting Immunosuppressive Neutrophils and Cancer-Driven Granulopoiesis," represents a collaboration between scientists at Tonix and Columbia University's Medical School and presents data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival and decreased metastases in animal models of gastric cancer. Citius Oncology Inc. announced the execution of a distribution services agreement with Cencora (formerly AmerisourceBergen), a global pharmaceutical services company. This agreement marks another significant step forward in the company's commercial launch strategy for LYMPHIR (denileukin diftitox-cxdl), its FDA-approved immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). This new agreement expands Citius Oncology's commercial distribution network, providing additional access and product availability upon launch. The agreement with Cencora, a leader in specialty pharmaceutical distribution and services, builds on a previously announced distribution services agreement to support long-term scalability and market reach of LYMPHIR. These recent developments underscore the dynamic and hopeful landscape of cancer treatment. From innovative therapies showing promise in clinical trials for conditions such as gastric cancer and late-onset Pompe disease, to strategic commercial moves ensuring that approved treatments like LYMPHIR can reach patients more effectively, the biopharmaceutical industry continues to push the boundaries of what's possible. For more information, visit Soligenix Inc. About NetworkNewsWire NetworkNewsWire ("NNW") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: NetworkNewsWire is powered by IBN DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Yahoo
15-07-2025
- Business
- Yahoo
A New Mining Model Is Emerging -- And Wall Street Is Paying Attention
NetworkNewsWire Editorial Coverage NEW YORK, July 15, 2025 /CNW/ -- For decades, mining has been defined by high-risk, high-capex exploration, where success hinges on one-in-a-thousand discoveries. Most juniors never reach production. Investors face dilution. Timelines stretch into decades. Most mining companies are uninvestable at scale because they are capital destroyers, cyclical and heavy capex, with high permitting and execution risk. ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) (Profile) is challenging that model. Instead of chasing theory, ESGold is redeveloping past-producing or legacy mine sites — sites with known volumes, historical grades and existing infrastructure. These are assets left behind not because they were depleted or economically unviable but because previous owners and operators lacked the resources and technology to develop them. With gold at an all-time high and demand for all types of minerals booming, now is the time for companies with the experience, insight and capital to position themselves in a market where potential has never been more promising and Wall Street has never been more interested. ESGold joins an elite group of mineral miners, including BHP Group Ltd. (NYSE: BHP), Barrick Mining Corporation (NYSE: GOLD), Franco-Nevada Corp. (NYSE: FNV) and Kinross Gold Corp. (NYSE: KGC) that are leveraging their expertise to make the most of this golden opportunity. For investors, bullion isn't enough — Wall Street wants leverage, scalability and cash flow. ESGold has developed a highly scalable, repeatable cash‑flow model that begins with low‑cost, low‑footprint tailings reprocessing and leverages the proceeds to fuel exploration and acquisition of legacy projects. The company has demonstrated proven execution and robust platform potential, leveraging clean processing and environmental remediation. ESGold's Montauban Project is now fully permitted and firmly under construction, marking a major milestone in the company's evolution from exploration to near-term production. ESGold's newly appointed CEO brings a compelling blend of finance expertise and resource-sector acumen to guide the company into its production and expansion phase. Click here to view the custom infographic of the ESGold Corp. editorial. A Different Opportunity Gold is hitting all-time highs ( U.S. debt is surging ( and central banks are buying more gold than at any point in history ( But for investors, bullion isn't enough — Wall Street wants leverage, scalability and cash flow. Today, the opportunity in the minerals space looks different than it ever has. With modern technology, elevated metals prices and environmental incentives, ESGold Corp.'s (CSE: ESAU) (OTCQB: ESAUF) model is to unlock value from legacy tailings — quickly, cleanly, and at low cost. No high-risk drilling campaigns. No decade-long permits. Just low capex, fast timelines and tangible economics. And that's not all. While extracting high margins, ESGold is also committed to cleaning up the environment. And because the approach is repeatable, this isn't just a mine — it's a scalable platform. Wall Street loves scalable models. ESGold provides exactly that: a system that generates cash flow, funds its own growth and turns forgotten sites into modern producers. ESGold is fully permitted, under construction, and on track to pour gold and silver within the next two quarters. This isn't the old mining story. It's a new chapter, one that aligns with institutional capital, clean-tech mandates, disciplined execution and, most importantly, profitability. Cash-Flow Model Built to Scale ESGold has developed a highly scalable, repeatable cash‑flow model that begins with low‑cost, low‑footprint tailings reprocessing and leverages the proceeds to fuel exploration and acquisition of legacy projects that meet its low‑capex, high‑margin criteria. The company's flagship Montauban Project in Quebec exemplifies this model ( With fully permitted infrastructure and a gravity separation circuit permitted for processing up to 1,000 tonnes per day of historic tailings, ESGold expects near-term gold, silver and mica production by late 2025 or early 2026. With processing costs at just C$29.83 per tonne and minimal environmental impact, the model generates robust free cash flow while cleaning up legacy sites ( Crucially, ESGold intentionally redirects this cash into systematic, district‑scale exploration. With more than 32,000 acres (or 13,000 hectares) of mineral claims and modern geophysical work, including Ambient Noise Tomography (ANT) scans to depths of 800-plus meters underway, the approach provides defined funding for discovering and expanding high‑grade legacy deposits. As CEO Gordon Robb states, the company has "laid the foundation for something extraordinary" ( This blueprint is built for replication across North America's estimated 500,000+ legacy mine and tailings sites ( By capitalizing on existing low‑capex tailings reprocessing before allocating proceeds to exploration or acquisition of new legacy deposits, ESGold's model aligns operational profitability with sustainability and environmental stewardship. Proven Execution, Platform Potential ESGold has demonstrated proven execution and robust platform potential, leveraging clean processing and environmental remediation to build a scalable gold and silver mining model. That foundation is reinforced by a focused leadership team and a favorable policy climate aligned with global sustainability goals. At its Montauban project, ESGold is advancing a gravity-based tailings processing facility, while exploring non-cyanide environmentally friendly extraction methods. This low-footprint, environmentally friendly operation is designed to clean up legacy tailings while generating nondilutive cash flow, setting the stage for redeployment into further exploration and redevelopment efforts ( In addition, the company is actively engaging with Quebec and Canadian governments, seeking nondilutive funding to support construction, equipment purchase and expansion, an approach that dovetails with regional clean industry incentives and sustainability mandates ( Through these partnerships, ESGold expects to create 20–30 direct jobs, plus additional roles in drilling and exploration, while affirming its commitment to sustainable resource stewardship. Permitted and Under Construction ESGold's Quebec-based Montauban Project is now fully permitted and firmly under construction, marking a major milestone in the company's evolution from exploration to near-term production. With more than 60% of the project's infrastructure already in place, financing has been secured, including a C$3.4 million raise, to initiate the final construction phase and mill assembly. This foundational work positions ESGold to transition decisively into gravity-based tailings processing, significantly reducing regulatory risk and accelerating the timeline to first gold and silver output ( In May 2025, ESGold completed the delivery and installation of key gravity separation equipment, including Humphrey spiral concentrators, which finalize the core processing circuit. Designed to handle up to 1,000 tonnes per day of historical tailings without chemical reagents, this system will recover gold, silver, and marketable mica, laying the groundwork for a clean, environmentally friendly pilot operation. Since late June, the team has expanded the Montauban mine building to 4,000 square feet, doubling its original size to accommodate personnel, control rooms, processing labs and a secure "gold room" for gold and silver storage, further evidencing serious capital deployment and operational scale-up ( Complementing the construction progress, onsite testing of spiral circuit concentrate is now underway, with metallurgical assays and updated geophysical surveys expected soon to optimize downstream recovery and exploration planning ( As a test-pilot model for fast-tracked, low-impact resource redevelopment, the fully permitted and under-construction Montauban Project offers a derisked path to production by year-end. It simultaneously validates ESGold's scalable, environmentally aligned platform — poised for expansion across the Americas — by demonstrating successful regulatory navigation, strategic infrastructure investment and operational readiness at scale. Cash Flow in Sight, Discovery Around the Corner ESGold is rapidly moving from project development to cash-flow generation, with first gold and silver production at the fully permitted Montauban Project. This milestone will complete the company's dual-track strategy — launching low-capex, gravity-based tailings processing while scaling up systematic exploration — so that operating revenues can directly fund discovery efforts across the broader property. The company's exploration engine is powered by Ambient Noise Tomography (ANT), a nonintrusive seismic imaging technique that captures natural and anthropogenic ground vibrations using highly sensitive geophones to map subsurface structures in 3D ( Unlike traditional seismic surveys, ANT passively records ambient seismic energy and converts it into deep-imaging models, enabling visualization up to depths of 800-plus meters, double the originally planned scope. This advanced deep-imaging capability allows ESGold to pinpoint structural repetitions, lens-like zones and deep-seated mineralized bodies beyond the reach of historical drilling. Pending the release of ANT results, ESGold could validate the presence of a district-scale volcanogenic massive sulfide (VMS) system at Montauban. Preliminary geophysical work has already identified a major conductive and magnetic anomaly in the southwestern portion of the property, reinforcing the VMS thesis ( If confirmed, this validation will support high-priority drilling targets and bolster a 3D geological model that combines ANT data with historical assay and VTEM records, paving the way for accelerated resource delineation. In essence, ESGold is not only nearing its inaugural production phase but also primed for transformational discovery. With cash flow in sight and geophysical confirmation around the corner, the company stands at a pivotal point: near-term gold and silver revenues that derisk and fund deeper drilling, and ANT-driven insights that may unveil a much larger mineralized footprint. The Right CEO for the Cycle Gordon Robb, ESGold's newly appointed CEO, brings a compelling blend of finance expertise and resource-sector acumen to guide the company into its production and expansion phase. With more than a decade of experience in global capital markets, Robb's background supports ESGold's ambitions for scalable, clean-mining initiatives ( His fluency in structuring complex deals and managing investor relations is expected to greatly benefit the company as it transitions into a near-term producer with long-term growth potential. Before joining ESGold, Robb served as business development and investor relations manager at Scottie Resources, where he was pivotal in capital-raising efforts and enhancing shareholder engagement. Under Robb's leadership, Scottie professionalized its investor communications and secured strategic funding, an achievement emblematic of Robb's deal-making mindset. Colleagues describe his tenure there as having an instrumental influence on the company's financial positioning and market credibility. At ESGold, Robb inherits a clean and environmentally responsible operation anchored by the Montauban tailings project, already under construction. "The Montauban Project is fully permitted, construction is well underway and a major discovery opportunity is unfolding alongside the tailings-to-cash flow model," Robb has stated. "We are building what the market has long been waiting for — a replicable, scalable clean mining company that delivers returns through both production and discovery, while minimizing environmental and permitting risk." Taken together, Robb's global finance pedigree, proven capital markets track record and strategic vision provide essential fuel for ESGold's dual ambitions: near-term cash flow through tailings reprocessing and district-scale discovery across legacy mine sites. His appointment signals to investors and stakeholders that ESGold has the executive depth necessary to execute both fronts with sophistication and discipline. Mining Moves, Wall Street Watches Wall Street is paying close attention as top-tier mining companies take strategic steps to align operations with next-generation growth drivers. For investors, these milestones signal a broader trend, where innovation and disciplined capital deployment are creating new opportunities across the resource space. BHP Group Ltd. (NYSE: BHP), a multinational mining and metals company, has announced that it will establish its first Industry AI Hub in Singapore ( The hub is designed to accelerate digital transformation and AI adoption in the mining and resources sector. The company noted that the hub will focus on solving BHP enterprise-wide challenges using AI technologies to improve safety and lift productivity. The hub of BHP AI specialists will also look at further integration of data-driven decisions, intelligence and automation into the company's core operations. BHP selected Singapore to further develop its AI capabilities for its vibrant innovation ecosystem, strong digital infrastructure and alignment with BHP's ambitions to scale technologies that deliver operational value. Barrick Mining Corporation (NYSE: GOLD) has released its 2024 sustainability report ( Titled "Beyond the Horizon," the report highlights Barrick's journey from its transformational merger in 2019 to becoming a leader in responsible mining, underscoring its commitment to sustainability-driven growth, community empowerment and environmental stewardship, focused on long-term value creation and measurable outcomes. As Barrick Mining Corporation enters a new growth phase through the rest of the decade, it has also recalibrated its greenhouse gas (GHG) emissions profile and reduction roadmap to align with its expanding production base, and increased renewable energy footprint supporting its ambitious Net Zero by 2050 target. Kinross Gold Corp. (NYSE: KGC), a Canadian-based global senior gold mining company, also published its 2024 sustainability report ( The report noted that the company had delivered a strong sustainability performance, including a $4 billion total benefit footprint through taxes, wages, procurement and community investment. "Kinross' commitment to Sustainability is deeply rooted in our values and culture, and we remain steadfast in our commitment to responsible mining," said Kinross CEO J. Paul Rollinson. "We prioritize health and safety and environmental stewardship, as well as providing sustainable benefits to the communities where we operate. Partnerships are core to our operating philosophy, and we strive to be a trusted partner that delivers impactful community investments." Franco-Nevada Corp. (NYSE: FNV), a leading gold-focused royalty and streaming company, has entered into an agreement to acquire an existing royalty package on the Côté Gold Mine in Ontario from a private third party for total cash consideration of $1,050 million ( The Côté Gold Mine is one of the newest, large scale, and most modern gold mines to be built in Canada with an already extensive gold mineral resource base of more than 16 million ounces of Measured and Indicated Mineral Resources and 4 million ounces of Inferred Mineral Resources. Franco-Nevada partnered with IAMGOLD Corporation and Sumitomo Metal Mining Co. Ltd. for the acquisition of the Royalty, which exclusively allows Franco-Nevada access to conduct detailed due diligence. For analysts and institutional investors, key developments underscore a compelling narrative: mining is no longer just about extraction, it's about transformation. Whether through strategic cash-flow models, scalability, or community value delivery, leading mining operations are positioning themselves for sustainable growth. As this evolution continues, Wall Street will be watching closely for companies that execute with both operational precision and forward-looking vision. For further information about ESGold Corporation, please visit ESGold Profile. About NetworkNewsWire NetworkNewsWire ("NNW") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: NetworkNewsWire is powered by IBN DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements. NetworkNewsWireNew York, OfficeEditor@ Logo - View original content to download multimedia: SOURCE NetworkNewsWire View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-07-2025
- Business
- Yahoo
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, 'Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs,' please visit: An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need — and an enormous market potential — for new and more effective cancer drugs. Calidi Biotherapeutics Inc. is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated. About Calidi Biotherapeutics Inc. Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical-stage, off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, visit the company's website at . NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company's newsroom at About NetworkNewsWire NetworkNewsWire ('NNW') is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: NetworkNewsWireNew York, NY 212.418.1217 Office Editor@ NetworkNewsWire is powered by IBNError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
09-07-2025
- Business
- Associated Press
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /CNW/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in the coming decades ( ). By 2050, the American Cancer Society estimates that annual cancer diagnoses will reach 35 million. While advances in treatment have improved outcomes for some patients, the demand for more effective therapies remains urgent — and the opportunity for innovation and market impact is significant. Calidi Biotherapeutics Inc. (NYSE American: CLDI) ( Profile ) is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors. Using engineered viruses to transport therapeutic payloads with precision, Calidi's technology aims to transform the landscape of cancer treatment. Though oncology is its initial focus, the company is also exploring broader applications in high-need areas such as autoimmune disorders. In doing so, Calidi is positioning itself among a select group of biotech innovators, including Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ImmunityBio Inc. (NASDAQ: IBRX), Crispr Therapeutics AG (NASDAQ: CRSP) and CytomX Therapeutics Inc. (NASDAQ: CTMX). Click here to view the custom infographic of the Calidi Biotherapeutics editorial. Immense Human Toll, Critical Need for Research Cancer continues to be one of the leading global health crises, accounting for roughly one in every six deaths worldwide ( ). Among the most prevalent forms are lung cancer, with 2.2 million new cases and 1.8 million deaths in 2020, followed by breast (2.26 million cases), colorectal (1.93 million cases) and prostate cancer (1.41 million cases). In the United States alone, cancer causes some 600,000 deaths each year, and projections estimate more than two million new diagnoses in 2025. These numbers reflect not only the immense human toll but also the strain cancer places on healthcare systems globally. The numbers also emphasize the critical need for ongoing investment in research and innovation. The global oncology drug market, valued at approximately $190.1 billion in 2023, is expected to surge to $564.5 billion by 2033, an 11.5% compound annual growth rate ( ). This growth is being fueled by continued advancements in early detection, targeted treatments, immunotherapy and personalized medicine — essential tools in the effort to reduce cancer's devastating impact. Redefining the Treatment Paradigm Calidi Biotherapeutics Inc. (NYSE American: CLDI) has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors, including hard-to-treat metastatic sites. Central to this innovation is Calidi's proprietary enveloped viral system, which encases therapeutic payloads in a human cell membrane. This 'envelope' allows the therapy to evade immune detection and travel through the bloodstream to reach distant cancer sites, where the genetic payload is activated to help eliminate tumors. The company's long-term R&D efforts, which began with stem cell-based delivery systems and evolved into advanced enveloped virotherapies, have produced a suite of novel platforms with strong therapeutic potential. Calidi's preclinical data, presented at leading scientific conferences and in investor updates, support its progress toward Investigational New Drug (IND) filings and possible strategic partnerships. With its focus on precise delivery, localized immune activation and systemic reach, Calidi is poised to help redefine the treatment paradigm for metastatic cancer — offering a safer, more effective way to deploy genetic medicines directly to the disease. Addressing Unmet Needs in Oncology Calidi Biotherapeutics is a clinical-stage biotech company focused on developing genetic medicines and proprietary, genetically engineered oncolytic viruses. One of its core innovations is the RedTail systemic antitumor virotherapy platform, which utilizes a specially engineered strain of vaccinia virus designed to selectively target tumors throughout the body ( ). This platform is capable of generating high levels of enveloped vaccinia viruses that are resistant to humoral immune responses, enabling the therapy to circulate systemically, reach tumor sites and deliver genetic payloads directly into the tumor microenvironment to drive tumor cell destruction. The lead therapeutic candidate from the RedTail platform — CLD-401 — is designed to address significant unmet needs in oncology. According to the company, CLD-401 is being developed to treat non-small cell lung cancer and other aggressive tumor types that currently have limited effective treatment options. Converting 'Cold' Tumors into 'Hot' Targets Calidi Biotherapeutics has made a major advance in addressing advanced and treatment-resistant cancers with CLD-401, its first drug candidate designed for systemic delivery. This investigational therapy reflects more than 10 years of Calidi's work in enveloped viral technology, leveraging a dual-action approach: destroying cancer cells while delivering genetic medicine intended to prevent recurrence at metastatic sites. Unlike traditional therapies that require localized injection, CLD-401 is administered intravenously, opening the door to a new generation of precision oncology treatments that can reach tumors anywhere in the body. At the heart of CLD-401's therapeutic effect is Calidi's proprietary RedTail platform. This platform uses an engineered oncolytic vaccinia virus encased in a protective envelope and enhanced with a chimeric CD55 receptor, making it highly resistant to immune system clearance and allowing it to circulate effectively to metastatic tumors. The virus carries an IL-15 superagonist payload, a potent genetic medicine that not only lyses cancer cells but also activates a strong immune response. By stimulating CD8+ T cells and natural killer (NK) cells, the therapy converts immunologically 'cold' tumors — those typically unresponsive to immune attack — into 'hot' targets, potentially improving outcomes in difficult-to-treat cancers. Preclinical studies have validated the platform's ability to deliver this effect. 'Of particular excitement is the rapid progress we have made with RedTail, the company's approach to systemically delivering genetic medicines to metastatic sites in patients with advanced cancer using our proprietarily engineered enveloped virus,' said Calidi CEO Dr. Eric Poma in a recent shareholder update ( ). 'RedTail represents the culmination of over a decade of meticulous research and innovation at Calidi to create what we believe is the most advanced systemic virotherapy platform. Advancing this novel platform is the company's main focus and priority.' Showcasing Promising Preclinical Data Calidi Biotherapeutics recently showcased promising preclinical data at two of the most prestigious oncology gatherings — the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) — demonstrating the tumor-destroying and relapse-preventing potential of its lead candidate, CLD-401. During the AACR Annual Meeting in April, Calidi presented findings titled 'Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites' ( ). The study highlighted how the RedTail platform's enveloped vaccinia virus, coated in a human-like extracellular membrane, can evade immune defenses, survive in circulation and reach multiple metastatic tumor sites following intravenous injection. The virus successfully delivered its genetic payload, including IL-15 superagonist, into challenging tumor models such as metastatic lung cancer. The data emphasized the platform's ability to bypass complement activation, significantly improving both circulation time and therapeutic effectiveness. Momentum continued at the ASCO Annual Meeting in June, where Calidi shared additional results underscoring the enhanced properties of CLD-401, which features a chimeric CD55 receptor to further resist immune system clearance. Once delivered to tumors, the virus released its IL-15 superagonist payload, which stimulated a strong immune response, particularly activating CD8+ T cells and natural killer (NK) cells, within the tumor microenvironment. These immune components are essential for generating long-term, durable antitumor activity ( ). Together, the AACR and ASCO presentations underline the dual strength of CLD-401: its ability to directly lyse tumor cells and its capacity to 'educate' the immune system to help prevent future recurrence. With systemic reach and targeted immune activation, RedTail positions Calidi's platform as a breakthrough in immuno-oncology, particularly for patients facing metastatic cancers with limited therapeutic options. 'Looking ahead, our roadmap for the next 18 months includes multiple critical milestones,' said Poma. 'We are working to complete IND-enabling studies ahead of an IND filing by the end of 2026 for our lead RedTail candidate that delivers IL-15 superagonist to tumor sites, CLD-401. Our clinical strategy includes an optimized dose-escalation study designed to swiftly demonstrate efficacy and validate the systemic administration of RedTail in patients with metastatic disease.' With strong preclinical validation and a clearly defined development path, Calidi is now preparing for clinical trials that could transform the way genetic medicines are delivered and used to combat cancer across the body. Making Strides with Breakthrough Therapies The biotech sector continues to push the boundaries of medical innovation, with several leading companies announcing major regulatory milestones and promising clinical advancements in an array of spaces. Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) recently received approval from the European Commission for its proprietary ALYFTREK(R), a new once-daily CFTR modulator for the treatment of cystic fibrosis ( ). A global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions, Vertex reported that ALYFTREK is approved in the European Union for people with CF aged six years of age and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for this medicine in the world. ImmunityBio Inc. (NASDAQ: IBRX), a leading immunotherapy company, announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of IBRX's Cancer BioShield(TM) platform ( ). Anchored by ANKTIVA(R) (nogapendekin alfa inbakicept-pmln), the platform is designed to treat lymphopenia in adult patients with refractory or relapsed solid tumors independent of tumor type who have progressed after first-line standard-of-care treatment, chemotherapy, radiation or immunotherapy. To date no treatment exists for lymphopenia, a depletion of critical lymphocytes responsible for immunogenic cell death, specifically natural killer (NK) cells, killer CD8+ T cells and CD4+ with memory T cells. Crispr Therapeutics AG (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, is reporting updates across its in vivo cardiovascular disease programs. These updated include new data for CTX310(TM), targeting ANGPTL3, as well as continued progress on CTX320(TM), targeting the LPA gene, and CTX340(TM), targeting the AGT gene ( ). Company officials noted that the additional data from its ongoing phase 1 clinical trial for CTX310 reinforces the potential of Crispr Therapeutics' platform to transform the treatment of serious cardiovascular diseases. CytomX Therapeutics Inc. (NASDAQ: CTMX), a leader in the field of masked, conditionally activated biologics, has updated its pipeline priorities and anticipated milestones for 2025 ( ). 'Our top strategic objective for 2025 is the development of CX-2051, a wholly-owned, first-in-class PROBODY ADC being developed initially in advanced metastatic colorectal cancer (CRC),' said CytomX CEO and chair Sean McCarthy. 'CX-2051 targets the previously undruggable highly expressed CRC antigen, EpCAM, and carries a topoisomerase-1 inhibitor payload. This novel ADC has the potential to make a meaningful difference in the treatment of heavily pretreated CRC patients, for whom the current standard of care remains inadequate and new treatment options are urgently needed.' As these companies press forward with bold science and regulatory success, they are setting the pace for a new era in disease treatment. With each breakthrough, hope grows for patients and families impacted by complex, underserved conditions. For more information, visit Calidi Biotherapeutics Inc. (NYSE American: CLDI). About NetworkNewsWire NetworkNewsWire ('NNW') is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: NetworkNewsWire is powered by IBN DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. 'Forward-looking statements' describe future expectations, plans, results, or strategies and are generally preceded by words such as 'may', 'future', 'plan' or 'planned', 'will' or 'should', 'expected,' 'anticipates', 'draft', 'eventually' or 'projected'. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements. NetworkNewsWire New York, NY 212.418.1217 Office [email protected] View original content to download multimedia: SOURCE NetworkNewsWire
